Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity.
Clade C subtype-specific HIV-1 infections are responsible for over 48% of global HIV-1 burden. Aiming to develop a vaccine that provides heterologous protection against HIV, a research group led by investigators from the Emory Vaccine Center at Emory University recently reported a novel clade C HIV-1 vaccine.
Many pathogens such as HIV, SARS-CoV-2, or those linked to influenza or cholera infect the host through mucosal surfaces and thus are thought to require both systemic and mucosal immune responses for effective management and protection.
Xenetic Biosciences and VolitionRx have entered into a research and development collaboration to develop neutrophil extracellular traps (NETs)-targeted, adoptive cell therapies for the treatment of cancer.
A study published in the July 28, 2022, online edition of Cell Chemical Biology shows that perturbation of thiamine (vitamin B1) metabolism inhibits Pseudomonas aeruginosa growth and sensitizes the bacterium to multiple antibiotics, opening up new avenues for much-needed combination therapies to treat pseudomonal infections.
Vaxxinity has selected VXX-401 to pursue as its anti-proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) vaccine candidate to treat hypercholesterolemia, and reported data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in nonhuman primates.
Caris Life Sciences and Xencor have entered into a multi-year strategic option and license agreement to research, develop and commercialize XmAb bispecific antibodies directed against novel targets for the treatment of patients with cancer.
Researchers at Beijing Institute of Pharmacology and Toxicology have reported the discovery of novel CRBN-recruiting epidermal growth factor receptor (EGFR) degraders as candidates for the treatment of non-small cell lung cancer (NSCLC). Synthesis and optimization of a series of CRBN-recruiting EGFR degraders led to the identification of compounds [I] and [II] as the lead candidates.
RSS